Earnings ·
Fate Therapeutics reported second quarter 2026 financial results and provided business updates
FATEFate Therapeutics Inc
Fate Therapeutics reported second quarter 2026 financial results and provided business updates. The company dosed the first patient in RECLAIM-LN, a Phase 2 potentially registrational trial for FT819 in lupus nephritis, with an expected enrollment of approximately 53 patients by the first half of 2028. FDA clearance was received for the FT839 IND application, advancing this dual CD19/CD38 CAR T-cell candidate into a Phase 1/2 basket trial for autoimmune diseases. Preliminary data for FT819 in systemic sclerosis showed positive responses with no serious adverse events reported. Financially, cash and investments decreased by $21 million to $153.8 million, supporting an operating runway into 2028. The company appointed Laura Hamill to its Board of Directors. Fate Therapeutics operates as a clinical-stage biopharmaceutical company developing iPSC-derived off-the-shelf cellular immunotherapies.